News
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028 -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
Transgene to present oral session on TG4050, an Individualized Neoantigen Therapeutic Vaccine, at World Vaccine Congress. Phase 1 findings in head and neck cancer and potential in early-stage treatment to be discussed -
